Search

Your search keyword '"Vaknin-Dembinsky, Adi"' showing total 341 results
Start Over Author "Vaknin-Dembinsky, Adi"
341 results on '"Vaknin-Dembinsky, Adi"'

4. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.

Author

Paul, Friedemann, Marignier, Romain, Palace, Jacqueline, Arrambide, Georgina, Asgari, Nasrin, Bennett, Jeffrey L, Cree, Bruce Anthony Campbell, De Sèze, Jérôme, Fujihara, Kazuo, Kim, Ho Jin, Hornby, Rebecca, Huda, Saif, Kissani, Najib, Kleiter, Ingo, Kuwabara, Satoshi, Lana-Peixoto, Marco, Law, Lisa, Leite, M Isabel, Pandit, Lekha, Pittock, Sean J, Quan, Chao, Ramanathan, Sudarshini, Rotstein, Dalia, Saiz, Albert, Sato, Douglas Kazutoshi, and Vaknin-Dembinsky, Adi

Subjects
Humans, Neuromyelitis Optica, Immunoglobulin G, Consensus, Delphi Technique, Aquaporin 4, Clinical Research, Good Health and Well Being
Abstract

Background and objectivesNeuromyelitis optica spectrum disorder (NMOSD) is a rare debilitating autoimmune disease of the CNS. Three monoclonal antibodies were recently approved as maintenance therapies for aquaporin-4 immunoglobulin G (AQP4-IgG)-seropositive NMOSD (eculizumab, inebilizumab, and satralizumab), prompting the need to consider best practice therapeutic decision-making for this indication. Our objective was to develop validated statements for the management of AQP4-IgG-seropositive NMOSD, through an evidence-based Delphi consensus process, with a focus on recommendations for eculizumab, inebilizumab, and satralizumab.MethodsWe recruited an international panel of clinical experts in NMOSD and asked them to complete a questionnaire on NMOSD management. Panel members received a summary of evidence identified through a targeted literature review and provided free-text responses to the questionnaire based on both the data provided and their clinical experience. Responses were used to generate draft statements on NMOSD-related themes. Statements were voted on over a maximum of 3 rounds; participation in at least 1 of the first 2 rounds was mandatory. Panel members anonymously provided their level of agreement (6-point Likert scale) on each statement. Statements that failed to reach a predefined consensus threshold (≥67%) were revised based on feedback and then voted on in the next round. Final statements were those that met the consensus threshold (≥67%).ResultsThe Delphi panel comprised 24 experts, who completed the Delphi process in November 2021 after 2 voting rounds. In round 1, 23/25 statements reached consensus and were accepted as final. The 2 statements that failed to reach consensus were revised. In round 2, both revised statements reached consensus. Twenty-five statements were agreed in total: 11 on initiation of or switching between eculizumab, inebilizumab, and satralizumab; 3 on monotherapy/combination therapy; 7 on safety and patient population considerations; 3 on biomarkers/patient-reported outcomes; and 1 on research gaps.DiscussionAn established consensus method was used to develop statements relevant to the management of AQP4-IgG-seropositive NMOSD. These international statements will be valuable for informing individualized therapeutic decision-making and could form the basis for standardized practice guidelines.

Published
2023

14. Mutation-specific pathophysiological mechanisms define different neurodevelopmental disorders associated with SATB1 dysfunction.

Author

den Hoed, Joery, de Boer, Elke, Voisin, Norine, Dingemans, Alexander, Guex, Nicolas, Wiel, Laurens, Nellaker, Christoffer, Amudhavalli, Shivarajan, Banka, Siddharth, Bena, Frederique, Ben-Zeev, Bruria, Bonagura, Vincent, Bruel, Ange-Line, Brunet, Theresa, Brunner, Han, Chew, Hui, Chrast, Jacqueline, Cimbalistienė, Loreta, Coon, Hilary, Délot, Emmanuèlle, Démurger, Florence, Denommé-Pichon, Anne-Sophie, Depienne, Christel, Donnai, Dian, Dyment, David, Elpeleg, Orly, Faivre, Laurence, Gilissen, Christian, Granger, Leslie, Haber, Benjamin, Hachiya, Yasuo, Abedi, Yasmin, Hanebeck, Jennifer, Hehir-Kwa, Jayne, Horist, Brooke, Itai, Toshiyuki, Jackson, Adam, Jewell, Rosalyn, Jones, Kelly, Joss, Shelagh, Kashii, Hirofumi, Kato, Mitsuhiro, Kattentidt-Mouravieva, Anja, Kok, Fernando, Kotzaeridou, Urania, Krishnamurthy, Vidya, Kučinskas, Vaidutis, Kuechler, Alma, Lavillaureix, Alinoë, Liu, Pengfei, Manwaring, Linda, Matsumoto, Naomichi, Mazel, Benoît, McWalter, Kirsty, Meiner, Vardiella, Mikati, Mohamad, Miyatake, Satoko, Mizuguchi, Takeshi, Moey, Lip, Mohammed, Shehla, Mor-Shaked, Hagar, Mountford, Hayley, Newbury-Ecob, Ruth, Odent, Sylvie, Orec, Laura, Osmond, Matthew, Palculict, Timothy, Parker, Michael, Petersen, Andrea, Pfundt, Rolph, Preikšaitienė, Eglė, Radtke, Kelly, Ranza, Emmanuelle, Rosenfeld, Jill, Santiago-Sim, Teresa, Schwager, Caitlin, Sinnema, Margje, Snijders Blok, Lot, Spillmann, Rebecca, Stegmann, Alexander, Thiffault, Isabelle, Tran, Linh, Vaknin-Dembinsky, Adi, Vedovato-Dos-Santos, Juliana, Schrier Vergano, Samantha, Vilain, Eric, Vitobello, Antonio, Wagner, Matias, Waheeb, Androu, Willing, Marcia, Zuccarelli, Britton, Kini, Usha, Newbury, Dianne, Kleefstra, Tjitske, Reymond, Alexandre, Fisher, Simon, and Vissers, Lisenka

Subjects
HPO-based analysis, SATB1, cell-based functional assays, de novo variants, intellectual disability, neurodevelopmental disorders, seizures, teeth abnormalities, Chromatin, Female, Genetic Association Studies, Haploinsufficiency, Humans, Male, Matrix Attachment Region Binding Proteins, Models, Molecular, Mutation, Mutation, Missense, Neurodevelopmental Disorders, Protein Binding, Protein Domains, Transcription, Genetic
Abstract

Whereas large-scale statistical analyses can robustly identify disease-gene relationships, they do not accurately capture genotype-phenotype correlations or disease mechanisms. We use multiple lines of independent evidence to show that different variant types in a single gene, SATB1, cause clinically overlapping but distinct neurodevelopmental disorders. Clinical evaluation of 42 individuals carrying SATB1 variants identified overt genotype-phenotype relationships, associated with different pathophysiological mechanisms, established by functional assays. Missense variants in the CUT1 and CUT2 DNA-binding domains result in stronger chromatin binding, increased transcriptional repression, and a severe phenotype. In contrast, variants predicted to result in haploinsufficiency are associated with a milder clinical presentation. A similarly mild phenotype is observed for individuals with premature protein truncating variants that escape nonsense-mediated decay, which are transcriptionally active but mislocalized in the cell. Our results suggest that in-depth mutation-specific genotype-phenotype studies are essential to capture full disease complexity and to explain phenotypic variability.

Published
2021

16. Cognitive impairments in autoimmune encephalitis: the role of autoimmune antibodies and oligoclonal bands.

Author

Rozenberg, Ayal, Shelly, Shahar, Vaknin-Dembinsky, Adi, Friedman-Korn, Tal, Benoliel-Berman, Tal, Spector, Polina, Yarovinsky, Natalya, Guber, Diana, Kapon, Lilach Gutter, Wexler, Yair, and Ganelin-Cohen, Esther

Subjects
MAGNETIC resonance imaging, LANGUAGE disorders, RECEPTOR antibodies, METHYL aspartate receptors, CEREBROSPINAL fluid, ANTI-NMDA receptor encephalitis
Abstract

Introduction: The presence of oligoclonal bands (OCBs) in cerebrospinal fluid (CSF) is a pivotal diagnostic marker for multiple sclerosis (MS). These bands play a crucial role in the diagnosis and understanding of a wide array of immune diseases. In this study, we explore the relationship between the cognitive profile of autoimmune encephalitis (AIE) and the presence of OCBs in CSF, with a particular emphasis on NMDA receptor antibodies. Methods: We studied a cohort of 21 patients across five tertiary centers, segregated into two distinct categories. One group comprised individuals who tested positive only for autoimmune encephalitis antibodies indicative of encephalitis, while the other group included patients whose CSF was positive for both autoimmune encephalitis antibodies and OCBs. Our investigation focused primarily on cognitive functions and behavioral alterations, supplemented by auxiliary diagnostic assessments such as CSF cell count, magnetic resonance imaging (MRI), and electroencephalogram (EEG) results, evaluated for the two patient groups. To validate our findings, we employed statistical analyses such as Fisher's exact test with Benjamini-Hochberg correction. Results: Our study included 21 patients, comprising 14 who were presented with only autoimmune encephalitis antibodies, and 7 who were dual-positive. Among these patients, we focused on those with NMDA receptor antibodies. Of these, five were dual positive, and nine were positive only for NMDA receptor antibodies. The dual-positive NMDA group, with an average age of 27 ± 16.47 years, exhibited significantly higher CSF cell counts (p=0.0487) and more pronounced language and attention deficits (p= 0.0264). MRI and EEG results did not differ significantly between the groups. Conclusions: Our results point to OCBs as an additional marker of disease severity in AIE, especially in NMDA receptor-antibody positive patients, possibly indicating a broader inflammatory process, as reflected in elevated CSF lymphocytes. Regular testing for OCBs in cases of suspected AIE may aid in disease prognosis and identification of patients more prone to language and attention disorders, improving diagnosis and targeting treatment for these cognitive aspects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Author

Dubois, Benedicte, Verhelst, Helene, Bojinova-Tchamova, Veneta, Mah, Jean, Cui, Li-Ying, Fang, Fang, Hao, Yunpeng, Jiang, Li, Li, Ling, Mao, Ding'An, Qiu, Wei, Tan, Guojun, Wu, Ye, Zhang, Meini, Zhou, Hongyu, Zhou, Shuizhen, Gross-Paju, Katrin, Cheuret, Emmanuel, Deiva, Kumaran, Edan, Giles, Vukusic, Sandra, Chrousos, George, Zafeiriou, Dimitrios, Achiron, Anat, Vaknin-Dembinsky, Adi, Yamout, Bassem, Laurynaitiene, Jurate, Vaiciene-Magistris, Nerija, Bojkovski, Vladimir, Trajkova, Vesna, Chaouki, Sana, Kissani, Najib, Neuteboom, Rinze, Palavra, Filipe, Belova, Anna, Boyko, Alexey, Evdoshenko, Evgeny, Kairbekova, Ekaterina, Malkova, Nadezhda, Shumilina, Maria, Skripchenko, Natalya, Nikolic, Dimitrije, Meca-Lallana, Jose, Triki, Chahnez Charfi, Chokri, Mhiri, Gouider, Riadh, Anlar, Banu, Gücüyener, Kivilcim, Hiz, Ayse Semra, Idiman, Egemen, Turkoglu, Recai, Yapici, Zuhal, Yilmaz, Unsal, Tantsura, Lyudmyla, Voloshyna, Nataliia, Lim, Ming, Wassmer, Evangeline, Cascione, Mark, Chitnis, Tanuja, LaGanke, Christopher, Rathke, Kevin, Scagnelli, John, Banwell, Brenda, Kappos, Ludwig, Arnold, Douglas L, Skripchenko, Natalia, Saubadu, Stephane, Hu, Wenruo, Benamor, Myriam, Le-Halpere, Annaig, Truffinet, Philippe, and Tardieu, Marc

Published
2021
Full Text
View/download PDF

26. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD

Author

Paul, Friedemann, primary, Marignier, Romain, additional, Palace, Jacqueline, additional, Arrambide, Georgina, additional, Asgari, Nasrin, additional, Bennett, Jeffrey L., additional, Cree, Bruce Anthony Campbell, additional, De Sèze, Jérôme, additional, Fujihara, Kazuo, additional, Kim, Ho Jin, additional, Hornby, Rebecca, additional, Huda, Saif, additional, Kissani, Najib, additional, Kleiter, Ingo, additional, Kuwabara, Satoshi, additional, Lana-Peixoto, Marco, additional, Law, Lisa, additional, Leite, M. Isabel, additional, Pandit, Lekha, additional, Pittock, Sean J., additional, Quan, Chao, additional, Ramanathan, Sudarshini, additional, Rotstein, Dalia, additional, Saiz, Albert, additional, Sato, Douglas Kazutoshi, additional, and Vaknin-Dembinsky, Adi, additional

Published
2023
Full Text
View/download PDF

28. Long-term Outcomes of MOGAD without Chronic Steroid-sparing Immunotherapy: a Multicenter Retrospective Cohort (S40.008)

Author

Tisavipat, Nanthaya, primary, Wilf-Yarkoni, Adi, additional, Flanagan, Eoin, additional, Redenbaugh, Vyanka, additional, Schwartzmann, Yoel, additional, Hellmann, Mark, additional, Tolkovsky, Assaf, additional, Stiebel-Kalish, Hadas, additional, Lotan, Itay, additional, Levy, Michael, additional, Salky, Rebecca, additional, Vaknin-Dembinsky, Adi, additional, Ganelin-Cohen, Esther, additional, Lopez, Alfonso, additional, Pittock, Sean, additional, and Chen, John, additional

Published
2023
Full Text
View/download PDF

29. The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis

Author

Asseyer, Susanna, primary, Asgari, Nasrin, additional, Bennett, Jeffrey, additional, Bialer, Omer, additional, Blanco, Yolanda, additional, Bosello, Francesca, additional, Camos-Carreras, Anna, additional, Carnero Contentti, Edgar, additional, Carta, Sara, additional, Chen, John, additional, Chien, Claudia, additional, Chomba, Mashina, additional, Dale, Russell C., additional, Dalmau, Josep, additional, Feldmann, Kristina, additional, Flanagan, Eoin P., additional, Froment Tilikete, Caroline, additional, Garcia-Alfonso, Carolina, additional, Havla, Joachim, additional, Hellmann, Mark, additional, Kim, Ho Jin, additional, Klyscz, Philipp, additional, Konietschke, Frank, additional, La Morgia, Chiara, additional, Lana-Peixoto, Marco, additional, Leite, Maria Isabel, additional, Levin, Netta, additional, Levy, Michael, additional, Llufriu, Sara, additional, Lopez, Pablo, additional, Lotan, Itay, additional, Lugaresi, Alessandra, additional, Marignier, Romain, additional, Mariotto, Sara, additional, Mollan, Susan P., additional, Ocampo, Cassandra, additional, Cosima Oertel, Frederike, additional, Olszewska, Maja, additional, Palace, Jacqueline, additional, Pandit, Lekha, additional, Peralta Uribe, José Luis, additional, Pittock, Sean, additional, Ramanathan, Sudarshini, additional, Rattanathamsakul, Natthapon, additional, Saiz, Albert, additional, Samadzadeh, Sara, additional, Sanchez-Dalmau, Bernardo, additional, Saylor, Deanna, additional, Scheel, Michael, additional, Schmitz-Hübsch, Tanja, additional, Shifa, Jemal, additional, Siritho, Sasitorn, additional, Sperber, Pia S., additional, Subramanian, Prem S., additional, Tiosano, Alon, additional, Vaknin-Dembinsky, Adi, additional, Mejia Vergara, Alvaro Jose, additional, Wilf-Yarkoni, Adi, additional, Zarco, Luis Alfonso, additional, Zimmermann, Hanna G., additional, Paul, Friedemann, additional, and Stiebel-Kalish, Hadas, additional

Published
2023
Full Text
View/download PDF

32. Identification of tissue-specific cell death using methylation patterns of circulating DNA

Author

Lehmann-Werman, Roni, Neiman, Daniel, Zemmour, Hai, Moss, Joshua, Magenheim, Judith, Vaknin-Dembinsky, Adi, Rubertsson, Sten, Nellgård, Bengt, Blennow, Kaj, Zetterberg, Henrik, Spalding, Kirsty, Haller, Michael J., Wasserfall, Clive H., Schatz, Desmond A., Greenbaum, Carla J., Dorrell, Craig, Grompe, Markus, Zick, Aviad, Hubert, Ayala, Maoz, Myriam, Fendrich, Volker, Bartsch, Detlef K., Golan, Talia, Sasson, Shmuel A. Ben, Zamir, Gideon, Razin, Aharon, Cedar, Howard, Shapiro, A. M. James, Glaser, Benjamin, Shemer, Ruth, and Dor, Yuval

Published
2016

35. Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel

Author

Weberpals, Janick, primary, Roumpanis, Spyros, additional, Barer, Yael, additional, Ehrlich, Sharon, additional, Jessop, Nikki, additional, Pedotti, Rosetta, additional, Vaknin-Dembinsky, Adi, additional, Brill, Livnat, additional, Chodick, Gabriel, additional, and Rouzic, Erwan Muros-Le, additional

Published
2022
Full Text
View/download PDF

37. Myelin oligodendrocyte glycoprotein antibody‐associated disease presenting with dystonia.

Author

Zveik, Omri, Benoliel Berman, Tal, Keadan, Tarek, Barhum, Khalil, Rechtman, Ariel, and Vaknin‐Dembinsky, Adi

Subjects
MYELIN oligodendrocyte glycoprotein, DYSTONIA, TRANSVERSE myelitis, SYMPTOMS, NEUROMYELITIS optica
Abstract

Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) commonly presents as optic neuritis or transverse myelitis. We report an atypical clinical presentation for MOGAD in a 28‐year‐old female experiencing right‐arm dystonic episodes. MRI scans demonstrated multifocal periventricular and subcortical lesions, including in the left centrum semiovale and corona radiata. Despite the atypical presentation, her clinical, serological, and radiographic features favor a MOGAD diagnosis. This report emphasizes the heterogeneity of MOGAD phenotypes and the need to consider MOGAD, even in a non‐typical presentation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments:Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

Author

Tur, Carmen, Dubessy, Anne Laure, Otero-Romero, Susana, Amato, Maria Pia, Derfuss, Tobias, Di Pauli, Franziska, Iacobaeus, Ellen, Mycko, Marcin, Abboud, Hesham, Achiron, Anat, Bellinvia, Angelo, Boyko, Alexey, Casanova, Jean Laurent, Clifford, David, Dobson, Ruth, Farez, Mauricio F., Filippi, Massimo, Fitzgerald, Kathryn C., Fonderico, Mattia, Gouider, Riadh, Hacohen, Yael, Hellwig, Kerstin, Hemmer, Bernhard, Kappos, Ludwig, Ladeira, Filipa, Lebrun-Frénay, Christine, Louapre, Céline, Magyari, Melinda, Mehling, Matthias, Oreja-Guevara, Celia, Pandit, Lekha, Papeix, Caroline, Piehl, Fredrik, Portaccio, Emilio, Ruiz-Camps, Isabel, Selmaj, Krzysztof, Simpson-Yap, Steve, Siva, Aksel, Sorensen, Per Soelberg, Sormani, Maria Pia, Trojano, Maria, Vaknin-Dembinsky, Adi, Vukusic, Sandra, Weinshenker, Brian, Wiendl, Heinz, Winkelmann, Alexander, Zuluaga Rodas, María Isabel, Tintoré, Mar, Stankoff, Bruno, Tur, Carmen, Dubessy, Anne Laure, Otero-Romero, Susana, Amato, Maria Pia, Derfuss, Tobias, Di Pauli, Franziska, Iacobaeus, Ellen, Mycko, Marcin, Abboud, Hesham, Achiron, Anat, Bellinvia, Angelo, Boyko, Alexey, Casanova, Jean Laurent, Clifford, David, Dobson, Ruth, Farez, Mauricio F., Filippi, Massimo, Fitzgerald, Kathryn C., Fonderico, Mattia, Gouider, Riadh, Hacohen, Yael, Hellwig, Kerstin, Hemmer, Bernhard, Kappos, Ludwig, Ladeira, Filipa, Lebrun-Frénay, Christine, Louapre, Céline, Magyari, Melinda, Mehling, Matthias, Oreja-Guevara, Celia, Pandit, Lekha, Papeix, Caroline, Piehl, Fredrik, Portaccio, Emilio, Ruiz-Camps, Isabel, Selmaj, Krzysztof, Simpson-Yap, Steve, Siva, Aksel, Sorensen, Per Soelberg, Sormani, Maria Pia, Trojano, Maria, Vaknin-Dembinsky, Adi, Vukusic, Sandra, Weinshenker, Brian, Wiendl, Heinz, Winkelmann, Alexander, Zuluaga Rodas, María Isabel, Tintoré, Mar, and Stankoff, Bruno

Abstract

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.

Published
2022

44. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

Author

Tur, Carmen, primary, Dubessy, Anne-Laure, additional, Otero-Romero, Susana, additional, Amato, Maria Pia, additional, Derfuss, Tobias, additional, Di Pauli, Franziska, additional, Iacobaeus, Ellen, additional, Mycko, Marcin, additional, Abboud, Hesham, additional, Achiron, Anat, additional, Bellinvia, Angelo, additional, Boyko, Alexey, additional, Casanova, Jean-Laurent, additional, Clifford, David, additional, Dobson, Ruth, additional, Farez, Mauricio F, additional, Filippi, Massimo, additional, Fitzgerald, Kathryn C, additional, Fonderico, Mattia, additional, Gouider, Riadh, additional, Hacohen, Yael, additional, Hellwig, Kerstin, additional, Hemmer, Bernhard, additional, Kappos, Ludwig, additional, Ladeira, Filipa, additional, Lebrun-Frénay, Christine, additional, Louapre, Céline, additional, Magyari, Melinda, additional, Mehling, Matthias, additional, Oreja-Guevara, Celia, additional, Pandit, Lekha, additional, Papeix, Caroline, additional, Piehl, Fredrik, additional, Portaccio, Emilio, additional, Ruiz-Camps, Isabel, additional, Selmaj, Krzysztof, additional, Simpson-Yap, Steve, additional, Siva, Aksel, additional, Sorensen, Per Soelberg, additional, Sormani, Maria Pia, additional, Trojano, Maria, additional, Vaknin-Dembinsky, Adi, additional, Vukusic, Sandra, additional, Weinshenker, Brian, additional, Wiendl, Heinz, additional, Winkelmann, Alexander, additional, Zuluaga Rodas, María Isabel, additional, Tintoré, Mar, additional, and Stankoff, Bruno, additional

Published
2022
Full Text
View/download PDF

47. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Author

Chitnis, Tanuja, primary, Banwell, Brenda, additional, Kappos, Ludwig, additional, Arnold, Douglas L, additional, Gücüyener, Kivilcim, additional, Deiva, Kumaran, additional, Skripchenko, Natalia, additional, Cui, Li-Ying, additional, Saubadu, Stephane, additional, Hu, Wenruo, additional, Benamor, Myriam, additional, Le-Halpere, Annaig, additional, Truffinet, Philippe, additional, Tardieu, Marc, additional, Dubois, Benedicte, additional, Verhelst, Helene, additional, Bojinova-Tchamova, Veneta, additional, Mah, Jean, additional, Fang, Fang, additional, Hao, Yunpeng, additional, Jiang, Li, additional, Li, Ling, additional, Mao, Ding'An, additional, Qiu, Wei, additional, Tan, Guojun, additional, Wu, Ye, additional, Zhang, Meini, additional, Zhou, Hongyu, additional, Zhou, Shuizhen, additional, Gross-Paju, Katrin, additional, Cheuret, Emmanuel, additional, Edan, Giles, additional, Vukusic, Sandra, additional, Chrousos, George, additional, Zafeiriou, Dimitrios, additional, Achiron, Anat, additional, Vaknin-Dembinsky, Adi, additional, Yamout, Bassem, additional, Laurynaitiene, Jurate, additional, Vaiciene-Magistris, Nerija, additional, Bojkovski, Vladimir, additional, Trajkova, Vesna, additional, Chaouki, Sana, additional, Kissani, Najib, additional, Neuteboom, Rinze, additional, Palavra, Filipe, additional, Belova, Anna, additional, Boyko, Alexey, additional, Evdoshenko, Evgeny, additional, Kairbekova, Ekaterina, additional, Malkova, Nadezhda, additional, Shumilina, Maria, additional, Skripchenko, Natalya, additional, Nikolic, Dimitrije, additional, Meca-Lallana, Jose, additional, Triki, Chahnez Charfi, additional, Chokri, Mhiri, additional, Gouider, Riadh, additional, Anlar, Banu, additional, Hiz, Ayse Semra, additional, Idiman, Egemen, additional, Turkoglu, Recai, additional, Yapici, Zuhal, additional, Yilmaz, Unsal, additional, Tantsura, Lyudmyla, additional, Voloshyna, Nataliia, additional, Lim, Ming, additional, Wassmer, Evangeline, additional, Cascione, Mark, additional, Chitnis, Tanuja, additional, LaGanke, Christopher, additional, Rathke, Kevin, additional, and Scagnelli, John, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results